CGT

554개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved554 programs
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV2-hAQP1 (AAV2-hAQP1)

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Paroti… · Grade 2 and 3 Late Xerostomia Caused by

#Grade2and3LateXerostomiaCausedby#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV2-hAQP1 Concentration 1 (AAV2-hAQP1 Concentration 1)

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Paroti… · Grade 2 and 3 Late Xerostomia Caused by

#Grade2and3LateXerostomiaCausedby#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV2-hAQP1 Concentration 2 (AAV2-hAQP1 Concentration 2)

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Paroti… · Grade 2 and 3 Late Xerostomia Caused by

#Grade2and3LateXerostomiaCausedby#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV2-hAQP1 Concentration 3 (AAV2-hAQP1 Concentration 3)

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Paroti… · Grade 2 and 3 Late Xerostomia Caused by

#Grade2and3LateXerostomiaCausedby#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV2-hAQP1 Concentration 4 (AAV2-hAQP1 Concentration 4)

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Paroti… · Grade 2 and 3 Late Xerostomia Caused by

#Grade2and3LateXerostomiaCausedby#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTAAVLimited DatastaleGenzyme, a Sanofi CompanyPhase 1

AAV2-sFLT01 (AAV2-sFLT01)

Macular Degeneration; Age-Related Maculopathies · Macular Degeneration

#MacularDegeneration#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTAAVLimited DatastaleCelosia Therapeutics Pty LtdPhase 1

AAV9 Gene therapy (AAV9 Gene therapy)

ALS (Amyotrophic Lateral Sclerosis) · ALS (Amyotrophic Lateral Sclerosis)

#ALSAmyotrophicLateralSclerosis#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTAAVLimited DatastaleUnlimited Biotechnology LLCPhase 2

AAV9-Follistatin gene therapy (AAV9-Follistatin gene therapy)

Age-related Muscle Decline · Age-related Muscle Decline

#Age-relatedMuscleDecline#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleAkouos, Inc.Phase 2

AAVAnc80-hOTOF via Akouos Delivery Device (AAVAnc80-hOTOF via Akouos Delivery Device)

Sensorineural Hearing Loss, Bilateral · Sensorineural Hearing Loss, Bilateral

#SensorineuralHearingLossBilatera#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleAkouos, Inc.Phase 2

AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism (AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism)

Sensorineural Hearing Loss, Bilateral · Sensorineural Hearing Loss, Bilateral

#SensorineuralHearingLossBilatera#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleJanssen Research & Development,…Phase 1

AAVCAGsCD59 (AAVCAGsCD59)

Dry Age-related Macular Degeneration · Dry Age-related Macular Degeneration

#DryAge-relatedMacularDegeneratio#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTAAVLimited DatastaleWeill Medical College of Cornel…Phase 2

AAVrh.10CUCLN2 (AAVrh.10CUCLN2)

Late Infantile Neuronal Ceroid Lipofuscinosis; Batten Disease · Late Infantile Neuronal Ceroid Lipofusci

#LateInfantileNeuronalCeroidLipof#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTAAVLimited DatastaleWeill Medical College of Cornel…Phase 1

AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies (AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies)

Batten Disease; Late-Infantile Neuronal Ceroid Lipofuscinosis · Batten Disease

#BattenDisease#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTAAVLimited DatastaleWeill Medical College of Cornel…Phase 1

AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies (AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies)

Batten Disease; Late-Infantile Neuronal Ceroid Lipofuscinosis · Batten Disease

#BattenDisease#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleInge Marie SvanePhase 1

ADP-TILIL7 (ADP-TILIL7)

Melanoma Stage III; Melanoma Stage IV · Melanoma Stage III

#MelanomaStageIII#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleCandel Therapeutics, Inc.Phase 2

ADV-TK (ADV-TK, adenovirus-thymidine kinase enzyme, ADV-TK (adenovirus-thymidine kinase enzyme) gene therapy)

Hepatocellular Carcinoma; Liver Transplantation · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleGuangzhou Anjie Biomedical Tech…Phase 2

AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells (AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells)

Advanced Breast Cancer; Breast Neoplasm Malignant Female · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleBeijing Immunochina Medical Sci…Phase 2

AMT-116 CAR-T cells (AMT-116 CAR-T cells)

Melanoma; Non-small Cell Lung Cancer · Melanoma

#Melanoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleBeijing Immunochina Medical Sci…Phase 2

AMT-253 CAR-T cells (AMT-253 CAR-T cells)

Melanoma; Non-small Cell Lung Cancer · Melanoma

#Melanoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleAvenCell Therapeutics, Inc.Phase 2

Allo-QuadCAR01-T (Allo-QuadCAR01-T)

Lymphoma Diffuse Large B-cell; Leukemia and Lymphoma · Lymphoma Diffuse Large B-cell

#LymphomaDiffuseLargeB-cell#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting

10 / 28 pages

← PreviousNext →